PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

Exclusion Criteria

• •1. Known brain metastasis or primary CNS malignancy
• •2. Has known psychiatric or substance abuse disorders.
• •3. Malnutrition, active infection, uncontrolled thyroid disorder, uncontrollable hypertension or diabetes mellitus, significant pulmonary disease and cardiovascular disease.
• •4. Currently using any other pharmacologic agents.
• •5. Subject who is unwilling to receive transfusions when, at the investigator's discretion, it is required to control her anemia.
• •6. Other medical conditions that necessitate chronic systemic use of steroids (e.g. use of prednisolone \> 10 mg daily or equivalent steroids fore more than 2 weeks).
• •7. ≤ 4 weeks from major surgery to randomization, including any procedure that requires general anesthetics.
• •8. Pain requiring opioid pain medication, however, over the counter analgesics such as acetaminophen or ibuprofen are allowed.
• •9. Use of monoamine oxidase inhibitors (MAOI) (such as Moclobemide).
• •10. Planning to start or complete any type of cancer therapy during the 8 weeks course of the study, once randomized on the study.
• •11. Use of any over the counter herbal/dietary supplement marketed for fatigue or energy.
• •12. Known history of hypersensitivity to Astragalus products.
• •13. Currently participating another interventional study or planning to join one in the upcoming 8 weeks after randomization.
• •14. Currently breast feeding.
• •15. With any other serious disease considered by the investigator not in the condition to enter into the trial.